Ayurcann Holdings Corp. (TSE:AYUR)
:AYUR
Top Page
Ayurcann Holdings Corp.
(AYUR)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.01
▼(-50.00% Downside)
Action:ReiteratedDate:02/25/26
The score is driven primarily by weak financial quality—ongoing losses and a stressed balance sheet with negative equity—alongside bearish technicals with price far below key moving averages. Strong revenue growth is a positive, but it is not yet translating into sustainable profitability or improved financial stability.
Ayurcann Holdings Corp. (AYUR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.95M
Dividend YieldN/A
Average Volume (3M)59.98K
Price to Earnings (P/E)―
Beta (1Y)-0.88
Revenue Growth15.95%
EPS Growth-1.81%
CountryCA
EmployeesN/A
SectorN/A
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding194,703,860
10 Day Avg. Volume17,939
30 Day Avg. Volume59,984
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-1.65
Price to Sales (P/S)0.16
P/FCF Ratio2.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ayurcann Holdings Corp. Business Overview & Revenue Model
Company Description
Ayurcann Holdings Corp. (AYUR) is a Canadian company specializing in the production and distribution of cannabis-derived products, focusing on innovative formulations that cater to both the medical and recreational markets. The company operates pr...
How the Company Makes Money
Ayurcann Holdings Corp. generates revenue through several key streams, primarily from the sale of its cannabis products, which include oils, capsules, and edibles. The company benefits from its proprietary extraction technologies, allowing it to p...
Ayurcann Holdings Corp. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Ayurcann Holdings Corp. Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
15.48
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYUR, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 15.48 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AYUR.
Ayurcann Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
49 Neutral | C$17.62M | -1.56 | -461.32% | ― | -46.59% | 8.26% | |
49 Neutral | C$20.21M | -2.55 | ― | ― | -100.00% | -8.70% | |
47 Neutral | C$14.65M | -4.56 | 899.59% | ― | ― | -80.42% | |
45 Neutral | C$8.46M | 5.19 | ― | ― | 15.64% | 58.47% | |
43 Neutral | C$6.59M | -3.18 | ― | ― | -100.00% | -192.62% | |
40 Underperform | C$1.95M | -1.54 | -271.33% | ― | 15.95% | -1.81% |
* Sector Average
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-66.67%
TSE:MVMD
Mountain Valley MD
0.05
0.02
66.67%
TSE:RVV
Revive Therapeutics
0.04
0.02
133.33%
TSE:PCLO
PharmaCielo
0.06
0.01
22.22%
TSE:SE
Sweet Earth Holdings
0.51
-0.02
-3.77%
TSE:LOBE
Lobe Sciences
0.08
0.05
200.00%
Ayurcann Holdings Corp. Corporate Events
Business Operations and StrategyDelistings and Listing ChangesLegal ProceedingsPrivate Placements and Financing
Ayurcann Seeks CCAA Creditor Protection and Launches Court‑Supervised Sale Process
Negative
Jan 30, 2026
Ayurcann Holdings Corp. and its subsidiary have obtained creditor protection under the Companies’ Creditors Arrangement Act, with Alvarez Marsal Canada Inc. appointed as monitor, in a move the board says is in the best interests of the comp...
Business Operations and StrategyFinancial Disclosures
Ayurcann Holdings Corp. Reports Strong Q1 2026 Sales and Market Expansion
Positive
Dec 1, 2025
Ayurcann Holdings Corp. reported Q1 2026 sales of $14,638,697, maintaining a strong presence in the Canadian cannabis market. The company is recognized as a top vape producer in Ontario, with a 5% share of the national vape market. Despite a decre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.